Additionally, dysregulation of mevalonate on the CSN6-HMGCS1-YAP1 axis has been found to specifically promote NAFLD-related liver cancer progression in HCC development (Li et al., 2024). Here, YAP1 is linked to metabolic dysfunction-associated steatotic liver disease.